Lantheus Holdings, Inc. (LNTH) Stock Score, Valuation & Financial Research
Lantheus Holdings, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 53/100.
Quick answer for LNTH
Lantheus Holdings, Inc. currently has a Wall Street Score of 53/100. The stored market price is $100.39. Its financial score is 19/100. Its valuation score is 59/100. These figures are a research snapshot, not a buy or sell recommendation.
What Lantheus Holdings, Inc. does
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the
LNTH financial snapshot
- Wall Street Score:
- 53/100
- Current price:
- $100.39
- Market capitalization:
- $6.54B
- Revenue:
- $1.55B
- Net income:
- $279.0M
- Free cash flow:
- $354.1M
- Cash:
- $498.6M
- Total debt:
- $625.8M
- EPS:
- 3.46
- P/E ratio:
- 29.0x
- Financial score:
- 19/100
- Valuation score:
- 59/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $354.1M, showing positive cash generation.
- The balance sheet shows $498.6M of cash versus $625.8M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 59/100, which Wall Street Score classifies as mixed within the model's valuation framework.
The financial score is 19/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research LNTH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.